Industry News

Zydus Lifesciences Limited has received approval from the National Medical Products Administration (NMPA), China for Venlafaxine Extended-Release (ER) Capsules, 75 mg and 150 mg.

Amgen announced detailed results from the Phase 3 VESALIUS-CV clinical trial, which showed that Repatha® (evolocumab) achieved statistically significant and clinically meaningful reductions in major adverse cardiovascular events (MACE) in high-risk adults without a prior heart attack or stroke

Novo Nordisk India and Emcure Pharma announced a strategic partnership to launch Poviztra, semaglutide injection 2.4 mg, in India.

Zydus Lifesciences Limited announced its unaudited consolidated financial results for the quarter and half year ended September 30, 2025, showcasing strong growth across all major business segments.

Pfizer Inc. issued a firm response following a ruling by the Court of Chancery of the State of Delaware that denied Pfizers request for a temporary restraining order to block Metsera, Inc. from terminating its merger agreement and accepting a competing proposal from Novo Nordisk A/S.

AstraZeneca has reported a strong set of results for the first nine months and third quarter of 2025, highlighting double-digit revenue growth, rising earnings, and record progress in its late-stage pipeline.

Through a new research and development funding agreement, the company will receive $700 million from Blackstone Life Sciences to support late-stage clinical development of sac-TMT.

In a compelling report released today, Novo Nordisk A/S (Bagsværd, Denmark) announced robust performance for the first nine months of 2025 along with noteworthy pipeline developments that reflect the company’s ambition to redefine the treatment of chronic and rare diseases.